|
GB9517780D0
(en)
*
|
1995-08-31 |
1995-11-01 |
Roslin Inst Edinburgh |
Biological manipulation
|
|
JP2001500725A
(en)
*
|
1996-08-19 |
2001-01-23 |
ユニヴァーシティー オヴ マサチューセッツ |
Embryonic or stem cell-like cell lines produced by interspecies nuclear transfer
|
|
US7696404B2
(en)
|
1996-08-19 |
2010-04-13 |
Advanced Cell Technology, Inc. |
Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
|
|
EP1060243A4
(en)
*
|
1998-03-02 |
2005-03-09 |
Univ Massachusetts |
EMBRYONIC CELL LINES OR STEM CELL-SIMILAR CELL LINES PRODUCED BY CORE TRANSPLANT BETWEEN DIFFERENT SPECIES
|
|
JP2002511234A
(en)
*
|
1998-03-16 |
2002-04-16 |
リレグ ピーティーワイ リミテッド |
Swine nuclear transfer
|
|
IL147179A0
(en)
*
|
1999-06-30 |
2002-08-14 |
Advanced Cell Tech Inc |
Cytoplasmic transfer to de-differentiate recipient cells
|
|
WO2001000794A1
(en)
*
|
1999-06-30 |
2001-01-04 |
Hwang, Woo-Suk |
Method for producing cloned tigers by employing inter-species nuclear transplantation technique
|
|
JP2003503044A
(en)
*
|
1999-06-30 |
2003-01-28 |
ワン,ウー−サク |
Method for producing human cloned embryos using interspecies nuclear transfer technology
|
|
WO2001000795A1
(en)
*
|
1999-06-30 |
2001-01-04 |
Hwang, Woo-Suk |
A method for producing cloned cows
|
|
US7621606B2
(en)
|
2001-08-27 |
2009-11-24 |
Advanced Cell Technology, Inc. |
Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
|
|
EP1214404A4
(en)
*
|
1999-09-14 |
2003-09-03 |
Univ Massachusetts |
LINES OF EMBRYONIC OR STRAIN CELLS PRODUCED BY NUCLEAR TRANSPLANTATION OF CROSS SPECIES AND TECHNIQUE FOR ENHANCING EMBRYONIC DEVELOPMENT BY GENETIC MODIFICATION OF DONOR CELLS OR TISSUE CULTURE.
|
|
NZ519346A
(en)
*
|
1999-12-20 |
2004-02-27 |
Univ Massachusetts |
Embryonic or stem-like cells produced by cross species nuclear transplantation
|
|
US20100167404A1
(en)
|
2005-08-03 |
2010-07-01 |
Advanced Cell Technology, Inc. |
Methods of Reprogramming Animal Somatic Cells
|
|
US10865383B2
(en)
|
2011-07-12 |
2020-12-15 |
Lineage Cell Therapeutics, Inc. |
Methods and formulations for orthopedic cell therapy
|
|
HRP20181648T1
(en)
|
2013-04-16 |
2019-01-25 |
Regeneron Pharmaceuticals, Inc. |
TARGET GENOMIC TARGET MODIFICATION
|
|
RS58159B1
(en)
|
2013-12-11 |
2019-03-29 |
Regeneron Pharma |
Methods and compositions for the targeted modification of a genome
|
|
MX388127B
(en)
|
2013-12-11 |
2025-03-19 |
Regeneron Pharma |
METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A GENOME.
|
|
CA2950173C
(en)
|
2014-06-06 |
2023-10-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for modifying a targeted locus
|
|
KR102386101B1
(en)
|
2014-06-26 |
2022-04-14 |
리제너론 파마슈티칼스 인코포레이티드 |
Methods and compositions for targeted genetic modifications and methods of use
|
|
ES2731437T3
(en)
|
2014-11-21 |
2019-11-15 |
Regeneron Pharma |
Methods and compositions for directed genetic modification through the use of guide RNA pairs
|
|
CN107208113A
(en)
|
2014-12-19 |
2017-09-26 |
瑞泽恩制药公司 |
Method and composition for carrying out targeting genetic modification by the multiple targeting of single step
|
|
KR102616160B1
(en)
|
2015-03-16 |
2023-12-22 |
리제너론 파마슈티칼스 인코포레이티드 |
Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
|
|
CN107920498A
(en)
|
2015-05-29 |
2018-04-17 |
瑞泽恩制药公司 |
The non-human animal destroyed with C9ORF72 locus
|
|
KR20180110107A
(en)
|
2016-02-16 |
2018-10-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Non-human animal with the mutated quinoleninase gene
|
|
CN113831407B
(en)
|
2016-05-20 |
2024-06-11 |
瑞泽恩制药公司 |
Methods for breaking immune tolerance using multiple guide RNAs
|
|
MX2019001211A
(en)
|
2016-07-29 |
2019-09-16 |
Regeneron Pharma |
Mice comprising mutations resulting in expression of c-truncated fibrillin-1.
|
|
MX381216B
(en)
|
2016-09-30 |
2025-03-12 |
Regeneron Pharma |
NON-HUMAN ANIMALS THAT HAVE A HEXANUCLEOTIDE REPEAT EXPANSION AT A C9ORF72 LOCUS.
|
|
US11064685B2
(en)
|
2017-02-27 |
2021-07-20 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal models of retinoschisis
|
|
KR102701443B1
(en)
|
2017-06-27 |
2024-09-04 |
리제너론 파마슈티칼스 인코포레이티드 |
Nonhuman animals containing the humanized ASGR1 locus
|
|
KR20200033259A
(en)
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
Methods and compositions for evaluating CRISPR / Cas-mediated destruction or deletion in vivo and CRISPR / Cas-induced recombination with exogenous donor nucleic acids
|
|
KR20200032117A
(en)
|
2017-07-31 |
2020-03-25 |
리제너론 파마슈티칼스 인코포레이티드 |
Evaluation of CRISPR / Cas-induced recombination with exogenous donor nucleic acids in vivo
|
|
US11130999B2
(en)
|
2017-07-31 |
2021-09-28 |
Regeneron Pharmaceuticals, Inc. |
Cas-ready mouse embryonic stem cells and mice and uses thereof
|
|
EP3585162B1
(en)
|
2017-09-29 |
2023-08-30 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized ttr locus and methods of use
|
|
AU2018366290B2
(en)
|
2017-11-10 |
2022-01-27 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising Slc30a8 mutation and methods of use
|
|
SG11202002456WA
(en)
|
2017-11-30 |
2020-04-29 |
Regeneron Pharma |
Non-human animals comprising a humanized trkb locus
|
|
WO2019183123A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
CN112969367B
(en)
|
2018-09-13 |
2023-04-07 |
瑞泽恩制药公司 |
Complement factor H gene knockout rat as C3 glomerulopathy model
|
|
AU2019403015B2
(en)
|
2018-12-20 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated repeat expansion
|
|
ES2966625T3
(en)
|
2019-04-04 |
2024-04-23 |
Regeneron Pharma |
Rodents comprising a humanized coagulation factor 12 locus
|
|
JP7610339B2
(en)
|
2019-06-04 |
2025-01-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Non-human animals containing a humanized TTR locus with a beta slip mutation and methods of use
|
|
CA3137764A1
(en)
|
2019-06-07 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized albumin locus
|
|
CA3217237A1
(en)
|
2019-06-27 |
2020-12-30 |
Regeneration Pharmaceuticals, Inc. |
Modeling tdp-43 proteinopathy
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
AU2021212668A1
(en)
|
2020-01-28 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized PNPLA3 locus and methods of use
|
|
EP4099821A1
(en)
|
2020-02-07 |
2022-12-14 |
Regeneron Pharmaceuticals, Inc. |
<smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
|
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
EP4171215A2
(en)
|
2020-06-26 |
2023-05-03 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ace2 locus
|
|
CN118488784A
(en)
|
2021-11-04 |
2024-08-13 |
瑞泽恩制药公司 |
Non-human animals comprising modified CACNG1 loci
|
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
EP4451863A1
(en)
|
2021-12-20 |
2024-10-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
|
CN113943712B
(en)
*
|
2021-12-20 |
2022-03-22 |
南京岚轩生物科技有限公司 |
Electrofusion buffer solution, preparation method thereof and electrofusion method
|
|
US20250194571A1
(en)
|
2022-02-07 |
2025-06-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
IL314673A
(en)
|
2022-02-11 |
2024-10-01 |
Regeneron Pharma |
Compositions and methods for screening 4R tau-targeted substances
|
|
EP4531554A1
(en)
|
2022-05-31 |
2025-04-09 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
|
EP4561348A2
(en)
|
2022-07-29 |
2025-06-04 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a modified transferrin receptor locus
|
|
KR20250044256A
(en)
|
2022-08-05 |
2025-03-31 |
리제너론 파마슈티칼스 인코포레이티드 |
Aggregation-resistant mutant of TDP-43
|
|
EP4593590A1
(en)
|
2022-09-29 |
2025-08-06 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
WO2024163650A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Animals comprising a modified klhdc7b locus
|
|
AU2024309884A1
(en)
|
2023-06-30 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for increasing homology-directed repair
|
|
WO2025122754A1
(en)
|
2023-12-07 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Gaa knockout non-human animals
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|